成立于1925年,主要致力于生物和抗体技术的研究,目前在日本保持领先地位。1994年,随着格拉诺赛特(粒细胞集落刺激因子; G-CSF)在中国的上市,自此拉开了中国事业的序幕。将肿瘤、骨关节疾病等定位为策略领域,加快引进新的产品进入中国市场,为中国患者的健康以及医疗机构作出一份贡献。
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows